-+ 0.00%
-+ 0.00%
-+ 0.00%

H.U. Group unit Fujirebio wins Health Canada licenses for Lumipulse neurology blood tests

PUBT·09/01/2026 05:00:17
Listen to the news
H.U. Group unit Fujirebio wins Health Canada licenses for Lumipulse neurology blood tests
  • H.U. Group unit Fujirebio secured Health Canada Class II medical device licenses for Lumipulse G NfL Blood, Lumipulse G pTau 217 Plasma assays.
  • Clearance allows clinical use in Canada on the automated LUMIPULSE G immunoassay platform, expanding access to blood-based neurology testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H.U. Group Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609010100BIZWIRE_USPR_____20260831_BW901156) on September 01, 2026, and is solely responsible for the information contained therein.